Exelon Articles
Insights on the US Alzheimer's disease market
3 December 2012
Final appraisal from UK’s NICE backs improved treatment access for early Alzheimer’s disease; SMC negative for Nexavar
18 January 2011
UK’s NICE does about turn on Alzheimer’s drugs but unable to recommend Merck & Co/J&J’s psoriatic arthritis drug Simponi
7 October 2010
Novartis posts 50% 4th-qtr 2009 profits rise and promotes drugs chief Jimenez to CEO; other top changes
26 January 2010
Novartis' 1st-qtr 2009 results boosted by new products
24 April 2009
UK doctors debate NHS drug top-ups
14 July 2008
UK doctors debate NHS drug top-ups
14 July 2008
Generic settlements over Exelon and Imitrex
28 January 2008
Galvus gets positive opinion from CHMP
24 December 2007
Novartis' Exelon not widely used by PCPs
3 December 2007
Novartis' Exelon patch launched in the UK
29 October 2007
Tokyo stocks to October 8, 2007
15 October 2007
Exelon gets EC OK for Alzheimer's disease
1 October 2007
NICE announce AD drug clarification "within 28 days"
20 August 2007
CHMP recommends approval Exelon patch
30 July 2007
Japan stock market week to July 16, 2007
23 July 2007
Stock Commentary - Europe - week to July 9, 2007
16 July 2007
Transdermal AD patch impresses in IDEAL trial
21 May 2007
Novartis' Exelon patch "better than tablet"
31 July 2006
UK's NICE appeal, consultation deadline
3 July 2006
UK anger over NICE ruling on Alzheimer
5 June 2006
Novartis launches Exelon in UK for PD dementia
5 June 2006
Stock Commentary - Europe - week to May 22, 2006
29 May 2006
Enrollment continues in Voyager's Ph III AD trial
24 April 2006
Stock Commentary - Europe
20 December 2004
Eisai/Pfizer's Alzheimer's disease drug Aricept is not cost-effective, says Lancet study
5 July 2004
Aricept compliance better than Exelon?
19 August 2002
H3 Pharma starts trials of Alzheimer's drug
1 July 2002
Exelon has long-term benefit in Alzheimer's
15 April 2002
Double-digit turnover growth for Novartis in 2001
11 February 2002
UK parliament
28 January 2002
Novartis' six-month 2001 net income jumps 10%, sales up 11%
16 August 2001
Novartis compares Exelon and Aricept
25 June 2001
Promising data for Forest's memantine
17 May 2001
Reminyl approved in USA for Alzheimer's
1 March 2001
Novartis expects five new products to drive growth in 2001
15 February 2001
Stock Commentary - Tokyo
1 February 2001
Stock Commentary - Tokyo
18 January 2001
Healthy revenue increase at Eisai
14 November 2000
First comparative study wins in favor of Aricept
28 September 2000
Novartis puts in solid 1st-half performance
21 August 2000
Novartis gains US approval for Exelon
25 April 2000
Novartis says 25% chance Zelmac NDA will not be accepted
22 February 2000
Novartis to increase investment in Spain
26 November 1999
Novartis upbeat at biannual R&D update
23 September 1999
Knoll to comarket Novartis' Exelon is Germany
19 August 1999
Bayer refiles ProMem dossier in USA
10 August 1999
Exelon approvable in USA
20 May 1999
Janssen files first dossier for galantamine
8 April 1999
Novartis to study Exelon in delaying Alzheimer's
26 March 1999
Further delay for Bayer's metrifonate in USA after FDA action letter
17 February 1999
Novartis 1998 sales down on forecasts
21 January 1999
Novartis India Launching Exelon
22 September 1998
Novartis Restructures After Disappointing First Half
1 September 1998
Novartis First Half Sales Under Expectations
16 July 1998
Delay For Novartis' Exelon In USA
14 July 1998
Forecasts For Global CNS Growth
23 June 1998
Euro CPMP April Plenary Meeting
18 June 1998
Stock Commentary Europe
28 May 1998
Novartis' Exelon
21 May 1998
Novartis' Exelon Cleared In First Major Market
14 May 1998
Modest Rise In Sales At Novartis Lower Than Expected
22 April 1998
Metrifonate Shows Efficacy In Behavior Dysfunction
11 March 1998
CPMP Recommends Novartis' Exelon
5 February 1998
1997: Another Good Year For New Chemical Entities
6 January 1998
1st Launches For Novartis' Exelon And CoDiovan
21 November 1997
Bayer Files For Metrifonate Approval In EU, Then USA
13 November 1997
Strong Advance In 1st-Half Profits At Novartis
29 August 1997
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
